Dr. John Cush RheumNow
2 years 2 months ago
EULAR 2024: Wednesday’s Topic Panel (RA) with RheumNow https://t.co/j83v8JeTXh
Dr. John Cush RheumNow
2 years 2 months ago
Transition from Psoriasis to PsA: Can we Prevent It?
Dr. Aurelie Najm discusses abstract OP0010 presented at Eular 2024 in Vienna, Austria.
https://t.co/MnHG9DgA3H https://t.co/Vht33gWVlC
Dr. John Cush RheumNow
2 years 2 months ago
Top 3 Messages About JAK Inhibitor Safety
Dr. Janet Pope discusses a debate she participated in at Eular 2024 in Vienna, Austria, and her top three messages regarding JAKi safety.
https://t.co/HKapiAIHSs https://t.co/QrO4pVNOTo
Dr. John Cush RheumNow
2 years 2 months ago
When patients say their joints are swollen, what does it mean?
Easy to dismiss it as a symptom, but this clinically suspect arthralgia cohort from Leiden shows:
- some correlation w/ MRI/USS findings
- predicts RA development
- still worthwhile!
#EULAR2024 POS0609 @drdavidliew https://t.co/cRl5ow1emE
Dr. John Cush RheumNow
2 years 2 months ago
ComOA- a cohort study from 3.4 million, 4 countries looked at OA (n=845K) & comorbidities. Tops were LBP (44%), HTN, (34%), allergy (21%), cataract (16%), vertigo (14%), depression (13%), DM (13%). After OA Dx: Fm, RA, PMR OP0230 #EULAR2024 https://t.co/GMVCHSfyt0 https://t.co/KFlacpHfAX
Dr. John Cush RheumNow
2 years 2 months ago
#POS0234 The effect of prophylactic Septrin in ANCA #vasculitis pts treated with RTX/CyC need further characterisation. Multicentre study in Korea showed protective effect on Serious Infection btw those treated vs not. Effect was seen in the 1st 3mths only
#EULAR2024 @Yuz6Yusof https://t.co/tOOvvVynKA
Dr. John Cush RheumNow
2 years 2 months ago
Another proof (if needed) that controlling Dz Activity in RA is a very important preventive measure in RA!
179 pts
ILD newly developed 9.5%
progressed 12.3%
no change 74.9%
improved 4.5%
5.7% in the LDA group 28.0% non-LDA group (p=0.006)
#EULAR2024 POS0408 @AurelieRheumo https://t.co/lKUY32KFiX
Dr. John Cush RheumNow
2 years 2 months ago
Impact of regulatory warning on JAK inhibitors
JAK inhibitors show promise for treating inflammatory rheumatic diseases, but ORAL surveillance 2022 found increased risk of MACE, cancer, and death.
https://t.co/BEYgUg1DF4 https://t.co/tsjOZ6emDg
Dr. John Cush RheumNow
2 years 2 months ago
Is a Biomarker for Adverse Pregnancy Outcomes on the Horizon?
Pregnancy in lupus patients raises concerns due to potential complications like preeclampsia, eclampsia, and increased mortality rates for both mother and baby.
https://t.co/Kv6F21UHze https://t.co/ya8lAkSLC2
Dr. John Cush RheumNow
2 years 2 months ago
Might Synovial Biopsy Predict Rheumatoid Treatment Responses?
Multi-modal analysis of rheumatoid arthritis (RA) synovitis pathotypes enables more accurate choices of first line cDMARDs treatment, suggesting a predictive value to synovial biopsy.
https://t.co/bMUzduZIz9 https://t.co/yFxCvoZukM
Childhood lupus (cSLE) is a rare multisystem disorder with significant associated morbidity, but evidence-based guidelines are sparse, and as such management is often based on clinical expertise.
Fertility in the context of RMDs is a daily concern for a lot of rheumatologists and patients.
EULAR this year proposed new fertility data, especially in Rheumatoid Arthritis, along with an update of the EULAR points to consider for use of antirheumatic drugs in reproduction, pregnancy and lactation.
Dr. John Cush RheumNow
2 years 2 months ago
EULAR 2024: Tuesday’s Topic Panel (PSA) with RheumNow https://t.co/j4I1bC9ROD
